Skip to content

Clinical trials

Observational Atherosclerosis trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Atherosclerosis Phase: Observational Country / region: United States Clear all

136 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
20012
20023
20035
20045
20053
20069
20079
200810
20096
20107
20119
20129
20133
20147
20154
20163
20172
20183
20196
20203
20212
20221
20231
20244
20254
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed100
Terminated11
Recruiting7
Active, not recruiting6
Unknown status6
Withdrawn6

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Heart, Lung, and Blood Institute (NHLBI)18
Massachusetts General Hospital9
Boston Scientific Corporation5
CardioDx4
National Institute of Allergy and Infectious Diseases (NIAID)4
Cedars-Sinai Medical Center3
Columbia University3
Duke University3
Mayo Clinic3
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Atherosclerosis136
Cardiovascular Diseases34
Coronary Artery Disease32
Coronary Disease17
Heart Diseases15
Myocardial Infarction13
Hypertension11
Stroke11
Diabetes Mellitus10
Angina Pectoris8

Trials

Showing 1 to 25 of 136. Each trial links to its page on Pharma Observatory.

36 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.